Log in

NASDAQ:KMPHKemPharm Stock Price, Forecast & News

-0.01 (-5.50 %)
(As of 05/25/2020 04:00 PM ET)
Today's Range
Now: $0.17
50-Day Range
MA: $0.25
52-Week Range
Now: $0.17
Volume2.36 million shs
Average Volume2.87 million shs
Market Capitalization$11.29 million
P/E RatioN/A
Dividend YieldN/A
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. It also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. The company has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. KemPharm, Inc. was founded in 2006 and is headquartered in Celebration, Florida.
Read More
KemPharm logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.98 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:KMPH



Sales & Book Value

Annual Sales$12.84 million
Book Value($1.04) per share


Net Income$-24,520,000.00


Market Cap$11.29 million
Next Earnings Date8/11/2020 (Estimated)

Receive KMPH News and Ratings via Email

Sign-up to receive the latest news and ratings for KMPH and its competitors with MarketBeat's FREE daily newsletter.

KemPharm (NASDAQ:KMPH) Frequently Asked Questions

How has KemPharm's stock been impacted by COVID-19 (Coronavirus)?

KemPharm's stock was trading at $0.2452 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KMPH shares have decreased by 30.0% and is now trading at $0.1717. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of KemPharm?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KemPharm in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for KemPharm.

When is KemPharm's next earnings date?

KemPharm is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for KemPharm.

How were KemPharm's earnings last quarter?

KemPharm Inc (NASDAQ:KMPH) posted its quarterly earnings results on Tuesday, May, 12th. The specialty pharmaceutical company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of $0.01 by $0.12. The specialty pharmaceutical company earned $2.09 million during the quarter, compared to analyst estimates of $5.80 million. View KemPharm's earnings history.

What price target have analysts set for KMPH?

2 brokers have issued twelve-month price targets for KemPharm's stock. Their forecasts range from $1.05 to $1.50. On average, they expect KemPharm's stock price to reach $1.28 in the next year. This suggests a possible upside of 642.6% from the stock's current price. View analysts' price targets for KemPharm.

What are Wall Street analysts saying about KemPharm stock?

Here are some recent quotes from research analysts about KemPharm stock:
  • 1. According to Zacks Investment Research, "KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. " (11/23/2019)
  • 2. HC Wainwright analysts commented, "Our $3 12-month target is based on a 65% probability of success adjusted DCF including profit split from Apadaz—approved and partnered prodrug of IR hydrocodone, pilot launching in 2H19—and royalties and milestones from KP415 from partner GPC. We project peak $23M KP415 revenue to KMPH at 100% gross margins. Both have IP into the 2030s. We see most near-term revenue solely from milestones, before product royalties and profit share accelerate in 2022-2023, with KemPharm sustainable profitability in 2023." (9/5/2019)

Has KemPharm been receiving favorable news coverage?

Press coverage about KMPH stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. KemPharm earned a news impact score of 1.4 on InfoTrie's scale. They also assigned news headlines about the specialty pharmaceutical company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the stock's share price in the near term. View the latest news aboutKemPharm.

Who are some of KemPharm's key competitors?

What other stocks do shareholders of KemPharm own?

Who are KemPharm's key executives?

KemPharm's management team includes the following people:
  • Dr. Travis C. Mickle, Co-Founder, Chairman, Pres & CEO (Age 46)
  • Dr. Sven Guenther, Exec. VP of R&D (Age 47)
  • Mr. Gordon K. Johnson, Chief Bus. Officer (Age 67)
  • Ms. Christal M. M. Mickle, Co-Founder and VP of Operations & Product Devel. (Age 40)
  • Mr. R. LaDuane Clifton CPA, CFO, Sec. & Treasurer (Age 47)

When did KemPharm IPO?

(KMPH) raised $60 million in an initial public offering on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

What is KemPharm's stock symbol?

KemPharm trades on the NASDAQ under the ticker symbol "KMPH."

Who are KemPharm's major shareholders?

KemPharm's stock is owned by a number of retail and institutional investors. Top institutional investors include RDA Financial Network (0.50%). Company insiders that own KemPharm stock include Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton, Timothy J Sangiovanni and Travis C Mickle. View institutional ownership trends for KemPharm.

Which institutional investors are buying KemPharm stock?

KMPH stock was bought by a variety of institutional investors in the last quarter, including RDA Financial Network. Company insiders that have bought KemPharm stock in the last two years include Delaware Street Capital Master, Gordon K Johnson, R Laduane Clifton, Timothy J Sangiovanni, and Travis C Mickle. View insider buying and selling activity for KemPharm.

How do I buy shares of KemPharm?

Shares of KMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is KemPharm's stock price today?

One share of KMPH stock can currently be purchased for approximately $0.17.

How big of a company is KemPharm?

KemPharm has a market capitalization of $11.29 million and generates $12.84 million in revenue each year. The specialty pharmaceutical company earns $-24,520,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. KemPharm employs 33 workers across the globe.

What is KemPharm's official website?

The official website for KemPharm is www.kempharm.com.

How can I contact KemPharm?

KemPharm's mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The specialty pharmaceutical company can be reached via phone at 321-939-3416 or via email at jrand[email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.